ArticleTranslational lung cancer research2025
Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab.
Takaaki Tokito et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.